Latest News

Epilepsy community seeks redefinition of bioequivalence from FDA

For several years, epilepsy practitioners have questioned the U.S. Food and Drug Administration?s (FDA) definition of bioequivalence as it applies to narrow therapeutic index (NTI) drugs, such as those used for epilepsy. In response to these concerns, the FDA has sponsored 3 studies of antiepileptic drugs and also convened an advisory board to help determine which drugs are NTI.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Want to boost your toddler's development? Put a toy chicken on your head

  • Study sheds surprising light on the causes of cerebral palsy

  • If you're using drugs, scientists want to help you avoid addiction

  • With racial segregation declining between neighborhoods, segregation now taking new form

  • Gene variants modifying Huntington's symptom onset may lead to new therapeutic strategies

  • Prescription for medical students: A day at the art museum?

  • Aquariums deliver health and wellbeing benefits

  • Teaching med students about health disparities builds their confidence

  • Antibiotics increase risk of hearing loss in patients with deadly bacterial infections

  • Changing clocks, changing seasons: Scientists find role for neuronal plasticity

  •